Ulcerative Colitis-Pipeline Review, H1 2017

Ulcerative Colitis-Pipeline Review, H1 2017


  • Products Id :- GMDHC9238IDB
  • |
  • Pages: 409
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Ulcerative Colitis-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ulcerative Colitis-Pipeline Review, H1 2017, provides an overview of the Ulcerative Colitis (Gastrointestinal) pipeline landscape.

Ulcerative Colitis (Colitis ulcerosa or UC) is a chronic disease mainly of the large intestine or colon and a type of Inflammatory Bowel Disease (IBD). The disease is characterized by open sores and ulcers in the colon. The risk factors for UC include smoking, family history of the disease, liver disease, colon cancer, depression, and severe dehydration. Common symptoms of ulcerative colitis include rectal bleeding, abdominal pain, and diarrhea. Treatment options for ulcerative colitis include surgery (removal of colon) or drug therapy with aminoasylates (ASA), immunomodulators, and corticosteroids.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ulcerative Colitis-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Ulcerative Colitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ulcerative Colitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Ulcerative Colitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 5, 14, 32, 25, 53, 9 and 3 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 12 and 1 molecules, respectively.

Ulcerative Colitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Ulcerative Colitis (Gastrointestinal).

The pipeline guide reviews pipeline therapeutics for Ulcerative Colitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Ulcerative Colitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Ulcerative Colitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Ulcerative Colitis (Gastrointestinal)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Ulcerative Colitis (Gastrointestinal).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Ulcerative Colitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

Introduction 6

Ulcerative Colitis-Overview 7

Ulcerative Colitis-Therapeutics Development 8

Ulcerative Colitis-Therapeutics Assessment 27

Ulcerative Colitis-Companies Involved in Therapeutics Development 41

Ulcerative Colitis-Drug Profiles 84

Ulcerative Colitis-Dormant Projects 375

Ulcerative Colitis-Discontinued Products 381

Ulcerative Colitis-Product Development Milestones 383

Appendix 393

List of Figures

Number of Products under Development for Ulcerative Colitis, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Top 10 Routes of Administration, H1 2017

Number of Products by Stage and Top 10 Routes of Administration, H1 2017

Number of Products by Top 10 Molecule Types, H1 2017

Number of Products by Stage and Top 10 Molecule Types, H1 2017

List of Tables

Number of Products under Development for Ulcerative Colitis, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..5), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Products under Development by Companies, H1 2017 (Contd..5), H1 2017

Products under Development by Companies, H1 2017 (Contd..6), H1 2017

Products under Development by Companies, H1 2017 (Contd..7), H1 2017

Products under Development by Companies, H1 2017 (Contd..8), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Ulcerative Colitis-Pipeline by 4D Pharma PLC, H1 2017

Ulcerative Colitis-Pipeline by AbbVie Inc, H1 2017

Ulcerative Colitis-Pipeline by AbGenomics International Inc, H1 2017

Ulcerative Colitis-Pipeline by Abivax SA, H1 2017

Ulcerative Colitis-Pipeline by Adello Biologics LLC, H1 2017

Ulcerative Colitis-Pipeline by Advinus Therapeutics Ltd, H1 2017

Ulcerative Colitis-Pipeline by Aerpio Therapeutics Inc, H1 2017

Ulcerative Colitis-Pipeline by Akebia Therapeutics Inc, H1 2017

Ulcerative Colitis-Pipeline by Allergan Plc, H1 2017

Ulcerative Colitis-Pipeline by Am-Pharma BV, H1 2017

Ulcerative Colitis-Pipeline by Amgen Inc, H1 2017

Ulcerative Colitis-Pipeline by Aptevo Therapeutics Inc, H1 2017

Ulcerative Colitis-Pipeline by Arena Pharmaceuticals Inc, H1 2017

Ulcerative Colitis-Pipeline by Atlantic Bio Sci LLC, H1 2017

Ulcerative Colitis-Pipeline by Atlantic Healthcare Plc, H1 2017

Ulcerative Colitis-Pipeline by Blueberry Therapeutics Ltd, H1 2017

Ulcerative Colitis-Pipeline by Boehringer Ingelheim GmbH, H1 2017

Ulcerative Colitis-Pipeline by Bristol-Myers Squibb Company, H1 2017

Ulcerative Colitis-Pipeline by Celgene Corp, H1 2017

Ulcerative Colitis-Pipeline by ChemoCentryx Inc, H1 2017

Ulcerative Colitis-Pipeline by ChironWells GmbH, H1 2017

Ulcerative Colitis-Pipeline by Circle33 LLC, H1 2017

Ulcerative Colitis-Pipeline by Coherus BioSciences Inc, H1 2017

Ulcerative Colitis-Pipeline by Cosmo Pharmaceuticals NV, H1 2017

Ulcerative Colitis-Pipeline by Dr. August Wolff GmbH & Co KG Arzneimittle, H1 2017

Ulcerative Colitis-Pipeline by Dr. Falk Pharma GmbH, H1 2017

Ulcerative Colitis-Pipeline by EA Pharma Co Ltd, H1 2017

Ulcerative Colitis-Pipeline by Eli Lilly and Company, H1 2017

Ulcerative Colitis-Pipeline by Enceladus Pharmaceuticals BV, H1 2017

Ulcerative Colitis-Pipeline by Enterome Bioscience SA, H1 2017

Ulcerative Colitis-Pipeline by Ferring International Center SA, H1 2017

Ulcerative Colitis-Pipeline by Galapagos NV, H1 2017

Ulcerative Colitis-Pipeline by Genentech Inc, H1 2017

Ulcerative Colitis-Pipeline by Genor BioPharma Co Ltd, H1 2017

Ulcerative Colitis-Pipeline by GlaxoSmithKline Plc, H1 2017

Ulcerative Colitis-Pipeline by iCo Therapeutics Inc., H1 2017

Ulcerative Colitis-Pipeline by Immune Therapeutics Inc, H1 2017

Ulcerative Colitis-Pipeline by Inception Sciences Inc, H1 2017

Ulcerative Colitis-Pipeline by InDex Pharmaceuticals AB, H1 2017

Ulcerative Colitis-Pipeline by Innovate Biopharmaceuticals Inc, H1 2017

Ulcerative Colitis-Pipeline by Intas Pharmaceuticals Ltd, H1 2017

Ulcerative Colitis-Pipeline by Johnson & Johnson, H1 2017

Ulcerative Colitis-Pipeline by Kaken Pharmaceutical Co Ltd, H1 2017

Ulcerative Colitis-Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2017

Ulcerative Colitis-Pipeline by LG Chem, Ltd., H1 2017

Ulcerative Colitis-Pipeline by LIPID THERAPEUTICS GmbH, H1 2017

Ulcerative Colitis-Pipeline by Lycera Corp, H1 2017

Ulcerative Colitis-Pipeline by Medestea Research & Production SpA, H1 2017

Ulcerative Colitis-Pipeline by Merck & Co Inc, H1 2017

Ulcerative Colitis-Pipeline by Merck KGaA, H1 2017

Ulcerative Colitis-Pipeline by Miyarisan Pharmaceutical Company Ltd, H1 2017

Ulcerative Colitis-Pipeline by Momenta Pharmaceuticals Inc, H1 2017

Ulcerative Colitis-Pipeline by Morphotek Inc, H1 2017

Ulcerative Colitis-Pipeline by Ogeda SA, H1 2017

Ulcerative Colitis-Pipeline by Oncobiologics Inc, H1 2017

Ulcerative Colitis-Pipeline by OSE Immunotherapeutics, H1 2017

Ulcerative Colitis-Pipeline by Panacea Biotec Ltd, H1 2017

Ulcerative Colitis-Pipeline by Pfizer Inc, H1 2017

Ulcerative Colitis-Pipeline by Principia Biopharma Inc, H1 2017

Ulcerative Colitis-Pipeline by Protab Ltd, H1 2017

Ulcerative Colitis-Pipeline by Protagonist Therapeutics Inc, H1 2017

Ulcerative Colitis-Pipeline by Protalix BioTherapeutics Inc, H1 2017

Ulcerative Colitis-Pipeline by Qu Biologics Inc, H1 2017

Ulcerative Colitis-Pipeline by Re-Pharm Ltd, H1 2017

Ulcerative Colitis-Pipeline by Rebiotix Inc, H1 2017

Ulcerative Colitis-Pipeline by Reliance Life Sciences Pvt Ltd, H1 2017

Ulcerative Colitis-Pipeline by Rock Creek Pharmaceuticals, Inc., H1 2017

Ulcerative Colitis-Pipeline by Sandoz International GmbH, H1 2017

Ulcerative Colitis-Pipeline by Sareum Holdings Plc, H1 2017

Ulcerative Colitis-Pipeline by Seres Therapeutics Inc, H1 2017

Ulcerative Colitis-Pipeline by Shire Plc, H1 2017

Ulcerative Colitis-Pipeline by Sigmoid Pharma Ltd, H1 2017

Ulcerative Colitis-Pipeline by Stelic Institute & Co Inc, H1 2017

Ulcerative Colitis-Pipeline by sterna biologicals Gmbh & Co KG, H1 2017

Ulcerative Colitis-Pipeline by Synergy Pharmaceuticals Inc, H1 2017

Ulcerative Colitis-Pipeline by Synlogic Inc, H1 2017

Ulcerative Colitis-Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017

Ulcerative Colitis-Pipeline by Theravance Biopharma Inc, H1 2017

Ulcerative Colitis-Pipeline by Thetis Pharmaceuticals LLC, H1 2017

Ulcerative Colitis-Pipeline by Tillotts Pharma AG, H1 2017

Ulcerative Colitis-Pipeline by TopiVert Ltd, H1 2017

Ulcerative Colitis-Pipeline by Trino Therapeutics Ltd, H1 2017

Ulcerative Colitis-Pipeline by UCB SA, H1 2017

Ulcerative Colitis-Pipeline by Ventria Bioscience, H1 2017

Ulcerative Colitis-Pipeline by Vivelix Pharmaceuticals Ltd, H1 2017

Ulcerative Colitis-Dormant Projects, H1 2017

Ulcerative Colitis-Dormant Projects, H1 2017 (Contd..1), H1 2017

Ulcerative Colitis-Dormant Projects, H1 2017 (Contd..2), H1 2017

Ulcerative Colitis-Dormant Projects, H1 2017 (Contd..3), H1 2017

Ulcerative Colitis-Dormant Projects, H1 2017 (Contd..4), H1 2017

Ulcerative Colitis-Dormant Projects, H1 2017 (Contd..5), H1 2017

Ulcerative Colitis-Discontinued Products, H1 2017

Ulcerative Colitis-Discontinued Products, H1 2017 (Contd..1), H1 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

4D Pharma PLC, AbbVie Inc, AbGenomics International Inc, Abivax SA, Adello Biologics LLC, Advinus Therapeutics Ltd, Aerpio Therapeutics Inc, Akebia Therapeutics Inc, Allergan Plc, Am-Pharma BV, Amgen Inc, Aptevo Therapeutics Inc, Arena Pharmaceuticals Inc, Atlantic Bio Sci LLC, Atlantic Healthcare Plc, Blueberry Therapeutics Ltd, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Celgene Corp, ChemoCentryx Inc, ChironWells GmbH, Circle33 LLC, Coherus BioSciences Inc, Cosmo Pharmaceuticals NV, Dr. August Wolff GmbH & Co KG Arzneimittle, Dr. Falk Pharma GmbH, EA Pharma Co Ltd, Eli Lilly and Company, Enceladus Pharmaceuticals BV, Enterome Bioscience SA, Ferring International Center SA, Galapagos NV, Genentech Inc, Genor BioPharma Co Ltd, GlaxoSmithKline Plc, iCo Therapeutics Inc., Immune Therapeutics Inc, Inception Sciences Inc, InDex Pharmaceuticals AB, Innovate Biopharmaceuticals Inc, Intas Pharmaceuticals Ltd, Johnson & Johnson, Kaken Pharmaceutical Co Ltd, Kyowa Hakko Kirin Co Ltd, LG Chem, Ltd., LIPID THERAPEUTICS GmbH, Lycera Corp, Medestea Research & Production SpA, Merck & Co Inc, Merck KGaA, Miyarisan Pharmaceutical Company Ltd, Momenta Pharmaceuticals Inc, Morphotek Inc, Ogeda SA, Oncobiologics Inc, OSE Immunotherapeutics, Panacea Biotec Ltd, Pfizer Inc, Principia Biopharma Inc, Protab Ltd, Protagonist Therapeutics Inc, Protalix BioTherapeutics Inc, Qu Biologics Inc, Re-Pharm Ltd, Rebiotix Inc, Reliance Life Sciences Pvt Ltd, Rock Creek Pharmaceuticals, Inc., Sandoz International GmbH, Sareum Holdings Plc, Seres Therapeutics Inc, Shire Plc, Sigmoid Pharma Ltd, Stelic Institute & Co Inc, sterna biologicals Gmbh & Co KG, Synergy Pharmaceuticals Inc, Synlogic Inc, Takeda Pharmaceutical Company Ltd, Theravance Biopharma Inc, Thetis Pharmaceuticals LLC, Tillotts Pharma AG, TopiVert Ltd, Trino Therapeutics Ltd, UCB SA, Ventria Bioscience, Vivelix Pharmaceuticals Ltd

select a license

Single User License
USD 2000 INR 129140
Site License
USD 4000 INR 258280
Corporate User License
USD 6000 INR 387420

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com